A large-scale vaccine study has officially begun in Finland, focusing on whether the shingles vaccine can help reduce the incidence of dementia among older adults. The study, named FinDementia, will enlist over 33,000 participants aged 76 and older from various regions across Finland. According to Arto Palmu, the research and medical director at the Finnish Vaccine Research (FVR), dementia is a severe condition with no known prevention methods to date. The insights gathered from this study may be crucial as global populations age and the incidence of dementia rises.

The FinDementia research initiative is being conducted in collaboration with vaccine manufacturer GlaxoSmithKline (GSK), selected welfare regions, and partnering pharmacies. It is planned to run from 2026 to 2030 and aims to robustly assess the shingles vaccine's potential for dementia prevention utilizing national registries. Participants will be routinely monitored, and their health data will provide a comprehensive understanding of the vaccine's efficacy when applied to the elderly demographic.

Enrollment for the study will open in April, allowing older adults and eligible individuals the chance to participate at designated FVR clinical sites and select welfare region facilities. The study's design will involve random assignment, with three-quarters of participants receiving the vaccine in question, providing a solid foundation for drawing statistical comparisons regarding its effectiveness against dementia. The outcomes of this study could have far-reaching implications for public health policy and strategies aimed at reducing the burden of dementia-related conditions in an increasingly aging society.